Explainer contrasts BPC-157 and TB-500 evidence, notes FDA distinction from thymosin beta-4
FDA briefing material states TB-500, an acetylated seven-amino-acid fragment, is not the same substance as thymosin beta-4, though websites use the names interchangeably.
PR
By Priya Raman · Science Reporter
Sep 18 15:28 ETSource: Medical News Bulletin
The wire
- 01A trade explainer compares BPC-157, a 15-amino-acid gastric peptide first described in 1993 at the University of Zagreb, with TB-500, the acetylated LKKTETQ fragment matching residues 17-23 of thymosin beta-4.
- 02Neither peptide is FDA-approved for any injury, and human BPC-157 work covers only ulcerative colitis, knee pain and interstitial cystitis, a point clinicians fielding patient questions can use.
- 03Much TB-500 evidence cited online actually comes from thymosin beta-4 or the non-acetylated fragment, which behave differently; the piece references research-grade sellers and no large human trial exists for either.
From the source
Read at medicalnewsbulletin.comBPC-157 vs TB-500: What’s the Difference?
Ask around about tissue repair or injury recovery, and the same two names keep surfacing: BPC-157 and TB-500. Both are research peptides. Longstanding research-grade suppliers such as Kylo Peptides sell them online for research use only.